Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Diligence And Janitors Needed To Keep Europe Innovating, Says Orphan Approval Pioneer

This article was originally published in Scrip

Executive Summary

The Australian company Clinuvel made a splash last year when it gained EU approval for its groundbreaking photoprotective therapy Scenesse (afamelanotide 16mg) – an orphan drug with a novel mode of action for a relatively unknown disease that was developed with the close involvement of patients who had received the treatment. As the European Medicines Agency prepares to consult on its new "PRIME" (priority medicines) scheme for giving more early support to drug developers, Clinuvel CEO Dr Philippe Wolgen explains what he thinks the agency really needs to do to foster true innovation in the EU.


Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts